Pharmaceutical CDMO Market Size, Share & Growth Report, 2033
The global pharmaceutical CDMO market size was estimated at USD 146.29 billion in 2023 and is projected to hit around USD 295.95 billion by 2033, growing at a CAGR of 7.3% during the forecast period from 2024 to 2033.
Key Takeaways:
Pharmaceutical CDMO Market Growth
Market growth can be attributed to the rising investments by CDMOs to expand new drug development and increasing demand for novel therapies. In addition, rising pharmaceutical Research & Development investments, the demand for genetic drugs, prevalence of cancer & age-related disorders, and the rising need for advanced therapeutics are key factors driving market growth.
In addition, market growth of biosimilars, biologics, personalized medicine, orphan drugs, companion diagnostics, and adaptive trial designs, among others, is anticipated to boost the demand for pharmaceutical CDMO. As companies explore new frontiers, the escalating requirement to adhere to regulations drives increased demand for specialized service providers proficient in contract development and manufacturing affairs.
Furthermore, key initiatives undertaken by the companies in this sector are also expected to boost market growth. In January 2022, Lonza partnered with HaemaLogiX-a developer of monoclonal antibodies-to manufacture myeloma drug candidate KappaMab monoclonal antibody. In December 2023, Innovent Biologics, Inc. extended its licensing deal with Synaffix B.V., a part of Lonza dedicated to advancing its clinical-stage platform technology for creating ADCs characterized by a best-in-class therapeutic index. Such biopharmaceutical initiatives are expected to accelerate the market growth of pharmaceutical contract development and manufacturing and services.
Furthermore, in many pharmaceutical companies, innovations, and speed-to-clinic factors are of critical importance. Small companies and specialty pharmaceutical players increasingly depend on third-party service providers to meet crucial industry requirements. Numerous CROs and CDMOs are comprehensive solution providers following a one-stop-shop service model. In this model, a CRO manages everything from API development to dosage form development, covering early development stages to commercialization. To deliver such services effectively, a CDMO needs a diverse array of enabling technologies & specialized handling capabilities tailored to address specific challenges. While these services tackle numerous problem statements, there exists considerable variability in product design capabilities among different CDMO players, which can be pivotal in scaling a product concept and bringing it to market.
Moreover, the extensive range & proficiency of a CDMO's skills across various technology types empower it to address the requirements of diverse customers. There is a growing willingness among customers to invest more in top-notch, consistently dependable CDMO services. Particularly, major pharmaceutical players are keen to reduce supplier interactions to integrate multiple processes throughout the value chain seamlessly. This encourages CDMOs to offer comprehensive solutions, enabling clients to manage operations cohesively & effortlessly.
Pharmaceutical CDMO Market Report Scope
| Report Attribute | Details |
| Market Size in 2024 | USD 156.97 Billion |
| Market Size by 2033 | USD 295.95 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 7.3% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Product, workflow, application, region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Lonza; Thermo Fisher Scientific, Inc.; Recipharm AB; Laboratory Corporation of America Holdings (LabCorp); Catalent, Inc.; WuXi AppTec, Inc.; Samsung Biologics; Piramal Pharma Solutions; Siegfried Holding AG; CordenPharma International; Cambrex Corporation; Bushu Pharmaceuticals Ltd.; Nipro Corporation |
Pharmaceutical CDMO Market Growth
Market growth can be attributed to the rising investments by CDMOs to expand new drug development and increasing demand for novel therapies. In addition, rising pharmaceutical Research & Development investments, the demand for genetic drugs, prevalence of cancer & age-related disorders, and the rising need for advanced therapeutics are key factors driving market growth.
In addition, market growth of biosimilars, biologics, personalized medicine, orphan drugs, companion diagnostics, and adaptive trial designs, among others, is anticipated to boost the demand for pharmaceutical CDMO. As companies explore new frontiers, the escalating requirement to adhere to regulations drives increased demand for specialized service providers proficient in contract development and manufacturing affairs.
Furthermore, key initiatives undertaken by the companies in this sector are also expected to boost market growth. In January 2022, Lonza partnered with HaemaLogiX-a developer of monoclonal antibodies-to manufacture myeloma drug candidate KappaMab monoclonal antibody. In December 2023, Innovent Biologics, Inc. extended its licensing deal with Synaffix B.V., a part of Lonza dedicated to advancing its clinical-stage platform technology for creating ADCs characterized by a best-in-class therapeutic index. Such biopharmaceutical initiatives are expected to accelerate the market growth of pharmaceutical contract development and manufacturing and services.
Furthermore, in many pharmaceutical companies, innovations, and speed-to-clinic factors are of critical importance. Small companies and specialty pharmaceutical players increasingly depend on third-party service providers to meet crucial industry requirements. Numerous CROs and CDMOs are comprehensive solution providers following a one-stop-shop service model. In this model, a CRO manages everything from API development to dosage form development, covering early development stages to commercialization. To deliver such services effectively, a CDMO needs a diverse array of enabling technologies & specialized handling capabilities tailored to address specific challenges. While these services tackle numerous problem statements, there exists considerable variability in product design capabilities among different CDMO players, which can be pivotal in scaling a product concept and bringing it to market.
Moreover, the extensive range & proficiency of a CDMO's skills across various technology types empower it to address the requirements of diverse customers. There is a growing willingness among customers to invest more in top-notch, consistently dependable CDMO services. Particularly, major pharmaceutical players are keen to reduce supplier interactions to integrate multiple processes throughout the value chain seamlessly. This encourages CDMOs to offer comprehensive solutions, enabling clients to manage operations cohesively & effortlessly.
Application Insights
Based on application, the oncology segment led the market with the largest revenue share of 21.92% in 2023 and is expected to grow at the fastest CAGR of 8.2% during the forecast period. The market is segregated into oncology, infectious diseases, neurological disorders, cardiovascular diseases, metabolic disorders, autoimmune diseases, respiratory diseases, ophthalmology, gastrointestinal disorders, hormonal disorders, hematological disorders, and others. Oncology is further sub-segmented into small molecules and biologics. Growth in the segment can be attributed to the increasing prevalence of cancer, growing demand for innovative & effective treatments, and favorable regulatory pathways. In addition, advancements in personalized medicine & targeted therapies have revolutionized cancer treatment, offering higher efficacy and fewer adverse effects. These factors are expected to create new possibilities for collaborations between pharmaceutical companies and CDMOs for innovative products targeting diseases. Further, high R&D investment in advanced therapeutics such as monoclonal antibodies, ADC, and several other biopharmaceuticals to minimize cancer disease burden is predicted to boost segmental revenue growth.
In addition, the infectious diseases market has witnessed dynamic trends and scenarios across various disease segments. The rising incidence of severe diseases, such as hepatitis, cholera, measles, chickenpox, and typhoid, has resulted in considerable market growth of the infectious diseases, owing to a steep increase in the demand for immunization against these diseases. In addition, pharmaceutical CDMOs focus on discovering, researching, and developing new drugs & therapies. Nevertheless, several molecular entities targeting immunization against fatal diseases, such as hepatitis C, leishmaniasis, paratyphoid fever, AIDS, Ebola, norovirus, and Chagas disease, are under development and research stages. Hence, the growing prevalence of such diseases creates the need for new drugs, which fuels the market growth.
Product Insights
Based on product, the active pharmaceutical ingredient (API) segment led the market with the largest revenue share of 81.11% in 2023. The market is segregated into API, and drug product. The active pharmaceutical ingredient (API) is further sub-segmented into type, synthesis, drug, and manufacturing. Market growth in this segment can be attributed to diverse formulations, accelerated demand for manufacturing processes, customer preference, and global acceptance. Moreover, increasing CDMOs focusing on new drug formulations is another factor propelling segment growth.
The API pharmaceutical CDMO segment is sub-segmented by type into traditional APIs, Highly Potent-API (HP-API), and biologics/large molecules. Traditional APIs use sophisticated R&D and commercial production phases. The traditional APIs segment is projected to grow at a CAGR of 5.2% during the forecast period due to rising R&D activities, growing cases of chronic diseases, increasing adoption of generics, and surging uptake of conventional active ingredients, such as small molecules. The synthesis segment is bifurcated into synthetic (solid & liquid) and biotech. The drug pharmaceutical CDMO segment is divided into innovative and generics. Manufacturing is bifurcated into continuous manufacturing & batch manufacturing. The continuous manufacturing segment is expected to witness at a lucrative CAGR during the forecast period, due to opportunities attributed to rapidly growing adoption and robust development of pipeline drugs. Global pharmaceutical & biotech companies are increasingly outsourcing drug development activities to CDMOs to stay competitive in an unstable economic environment. This has increased the requirement for continuous manufacturing of drugs.
In 2023, the drug product segment is anticipated to grow at a lucrative CAGR over the forecast period. The robust demand for drug products, such as oral solid dose, semisolid dose, liquid dose, and others, is expected to drive the segment. Besides, a growing R&D pipeline is expected to impact the market positively. In addition, the burden of chronic and infectious diseases is rising worldwide.
Work Flow Insights
Based on work-flow, The commercial segment led the market with the largest revenue share of 87.99% in 2023. The market is segregated into clinical and commercial. Some key factors contributing to the growth are strong CDMOs' expertise in drug development and manufacturing, integration of advanced drug development and manufacturing technologies in CDMOs, increasing R&D of innovative therapies, and expanding product portfolio. Moreover, commercial CDMOs cater cost-effective services within the reduced timeline, which is expected to contribute to market growth.
The clinical segment growth can be attributed to the increasing R&D activities for investigational drugs and innovations, supported by investments and funding for drug developments.
Regional Insights
The pharmaceutical CDMO market in North America is expected to grow at the fastest CAGR of 6.6% over the forecast period. This can be attributed to a growing investment in R&D of new drugs by pharmaceutical companies, which boosts the demand for pharmaceutical contract development and manufacturing services. The growth of pharmaceutical industry in the U.S. and Canada is a key factor contributing to market growth. In addition, the substantial presence of key market players and clinical trials are anticipated to drive market growth. In addition, stringent regulatory requirements, particularly in the U.S. & Canada, necessitate specialized knowledge & compliance expertise, making CDMOs an attractive option for navigating regulatory hurdles.
U.S. Pharmaceutical CDMO Market Trends
The pharmaceutical CDMO market in the U.S. held the largest share in 2023. Pharmaceutical companies are increasingly outsourcing their development & manufacturing activities to CDMOs to reduce costs, accelerate time-to-market, and access specialized expertise. This trend is fueling market growth in the U.S. as CDMOs expand to meet the increasing demand for outsourcing services. For instance, In May 2023, CordenPharma ventured into synthetic oligonucleotide manufacturing at its facility in Colorado.
Europe Pharmaceutical CDMO Market Trends
The pharmaceutical CDMO market in Europe is expected to grow at the significant CAGR during the forecast period, due to a growing number of pharmaceutical activities increasing the demand for CDMOs. Moreover, the growing trend of outsourcing services to European countries is expected to contribute to the increasing demand for pharmaceutical CDMO in this region.
The Germany pharmaceutical CDMO market held the largest share in 2023, owing to the market experiencing consolidation as larger companies acquire smaller ones. This consolidation strengthens the market position of the acquiring companies and allows them to improve operational efficiency & enhance competitiveness.
The pharmaceutical CDMO market in the UK is anticipated to grow at the fastest CAGR over the forecast period. Established market players in the region, such as Lonza Group, Piramal Pharma Solutions, and AbbVie Contract Manufacturing, which are actively involved in providing pharmaceutical contract development and manufacturing services, are expected to contribute to market growth.
Asia Pacific Pharmaceutical CDMO Market Trends
Asia Pacific held the market with the largest revenue share of 37.85% in 2023. This growth can be attributed to various factors, such as improved insurance schemes and improving economic conditions in the region, which allow patients to pay out-of-pocket pharmaceutical costs. In recent years, countries such as Singapore, China, and India have been observed to be major players in the pharmaceutical industry owing to their expanding manufacturing capabilities.
The pharmaceutical CDMO market in China held the largest share in 2023, due to growing partnership agreements between CDMO and pharmaceutical companies, supplementing China's pharmaceutical CDMO market growth. For instance, in September 2023, Chime Biologics, a Chinese CDMO, established a strategic partnership with Kings Pharm from South Korea.
The Japan pharmaceutical CDMO market is expected to grow at the fastest CAGR over the forecast period, due to rapid advancements in drug delivery technology, such as targeted drug delivery & sustained-release dosage forms, which drive pharmaceutical CDMO market growth.
The pharmaceutical CDMO market in India is anticipated to grow at the fastest CAGR over the forecast period, owing to low costs, the availability of industry experts, and the presence of WHO-cGMP-compliant facilities.
Recent Developments
Key Pharmaceutical CDMO Company Insights
The major players operating across the market focus on adopting in-organic strategic initiatives such as mergers, partnerships, acquisitions, etc. The prominent strategies companies adopt are service launches, mergers & acquisitions/joint ventures, mergers, partnership & agreements, expansions, and others to increase market presence & revenue and gain a competitive edge driving market growth. Hence, increasing adoption of in-organic strategic initiatives is highly anticipated to boost the market share of prominent players.
Key Pharmaceutical CDMO Companies:
The following are the leading companies in the pharmaceutical CDMO market. These companies collectively hold the largest market share and dictate industry trends.
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Pharmaceutical CDMO market.
By Product
By Workflow
By Application
By Region
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Regional Scope
1.1.2. Estimates and Forecast Timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. nova one advisor’s Internal Database
1.3.3. Secondary Sources
1.3.4. Primary Research
1.3.5. Details of Primary Research
1.4. Information or Data Analysis
1.4.1. Data Analysis Models
1.5. Market Formulation & Validation
1.5.1. Region Wise Market: Base Estimates
1.5.2. Global Market: CAGR Calculation
1.6. Model Details
1.6.1. Commodity Flow Analysis (Model 1)
1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
1.6.3. QFD Model Sizing & Forecasting (Model 3)
1.6.4. Bottom-Up Approach (Model 4)
1.7. Market Definitions
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. Objectives
1.10.1. Objective - 1
1.10.2. Objective - 2
1.10.3. Objective - 3
1.10.4. Objective - 4
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Technology outlook
2.2.2. Treatment outlook
2.2.3. Application outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Pharmaceutical CDMO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing consumption of biopharmaceuticals
3.2.1.2. Increasing demand for one-stop-shop CDMOs
3.2.1.3. Rising Demand for Advanced Therapeutics
3.2.1.4. Increasing outsourcing services by pharmaceutical companies
3.2.1.5. Upsurge in the number of clinical trials
3.2.1.6. Increasing pharmaceutical R&D investments
3.2.1.7. Growing demand for orphan drug discovery
3.2.2. Market Restraint Analysis
3.2.2.1. Compliance issues while outsourcing
3.2.2.2. Changing Scenarios within Developing Countries
3.2.2.3. Regulatory and Legal Compliance
3.2.2.4. Contractual Obligation
3.3. Pharmaceutical CDMO Market: Analysis Tools
3.3.1. PORTER’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.4. Industry Ecosystem Analysis
3.4.1. Supply Chain Analysis
3.4.2. Demand Analysis
3.4.3. Raw Material Analysis
3.4.3.1. GMP Material
3.4.3.1.1. Regulatory Landscape
3.4.3.1.2. Adoption Trend Analysis
3.4.3.1.3. Consumer Behavior Analysis
3.4.3.2. Non-GMP Material
3.4.3.2.1. Regulatory Landscape
3.4.3.2.2. Adoption Trend Analysis
3.4.3.2.3. Consumer Behavior Analysis
3.5. Technology Landscape
3.5.1. Integration of AI in pharmaceutical CDMO market
3.5.1.1. Current Dynamics and Future Trends
3.5.1.1.1. Drug Discovery and Design
3.5.1.1.2. AI-Assisted Drug Active Pharmaceutical Ingredient (API) Synthesis
3.5.1.1.3. Process Optimization
3.5.1.1.4. Supply Chain Management
3.5.1.1.5. Clinical Trial Optimization
3.5.1.1.6. Regulatory Compliance
3.6. Total Number of Clinical Trials by Phase & Region (2021 - 2023)
3.6.1. Total Number of Clinical Trials by Phase (2021 - 2023)
3.6.2. Total Number of Clinical Trials by Region (2021 - 2023)
3.6.2.1. Percentage of Clinical Trials by Major Countries in North America:
3.6.2.2. Percentage of Clinical Trials by Major Countries in Europe:
3.6.2.3. Percentage of Clinical Trials by Major Countries in Asia Pacific:
3.6.2.4. Percentage of Clinical Trials by Major Countries in Latin America:
3.6.2.5. Percentage of Clinical Trials by Major Countries in the Middle East & Africa:
3.6.3. Total Number of Clinical Trials by Therapeutic Area (2021 - 2023)
3.7. COVID-19 Impact Analysis
3.7.1. Covid-19 Impact on Pharmaceutical CDMO Market
3.7.2. Covid-19 Impact on Pharmaceutical Outsourcing Market
3.7.2.1. Long-term effects of the COVID-19 pandemic on pharmaceutical outsourcing on the Market
3.7.3. Post Covid-19 Impact and Recovery Analysis
3.7.3.1. Pre-pandemic bioCDMO Capacity Challenges
3.7.3.2. BioCDMO Industry Growth
3.7.3.3. Post-COVID-19 Revenue and Capacity Projections
3.7.3.4. COVID-19 Reformation Strategies
3.7.4. Covid-19 Impact on Key Market Players
Chapter 4. Pharmaceutical CDMO Market: Product Estimates & Trend Analysis
4.1. Definitions and Scope
4.1.1. API
4.1.2. Drug Product
4.2. Product Market Share, 2023 & 2030
4.3. Segment Dashboard
4.4. Global Pharmaceutical CDMO Market Movement Analysis
4.5. Global Pharmaceutical CDMO Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.5.1. API
4.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.2. Type
4.5.1.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.2.2. Traditional Active Pharmaceutical Ingredient (Traditional API)
4.5.1.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.2.3. Highly Potent Active Pharmaceutical Ingredient (HP-API)
4.5.1.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.2.4. Antibody Drug Conjugate (ADC)
4.5.1.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.2.5. Others
4.5.1.2.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.3. Synthesis
4.5.1.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.3.2. Synthetic
4.5.1.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.3.2.2. Solid
4.5.1.3.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.3.2.3. Liquid
4.5.1.3.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.3.3. Biotech
4.5.1.3.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.4. Drug
4.5.1.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.4.2. Innovative
4.5.1.4.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.4.3. Generics
4.5.1.4.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.5. Manufacturing
4.5.1.5.1. Continuous manufacturing
4.5.1.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.5.2. Batch manufacturing
4.5.1.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.2. Drug Product
4.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.2.2. Oral solid dose
4.5.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.2.3. Semi-solid dose
4.5.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.2.4. Liquid dose
4.5.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.2.5. Others
4.5.2.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 5. Pharmaceutical CDMO Market: Workflow Estimates & Trend Analysis
5.1. Definitions and Scope
5.1.1. Clinical
5.1.2. Commercial
5.2. Segment Dashboard
5.3. Global Pharmaceutical CDMO Market Movement Analysis
5.4. Global Pharmaceutical CDMO Market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
5.4.1. Clinical
5.4.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.4.2. Commercial
5.4.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 6. Pharmaceutical CDMO Market: Application Estimates & Trend Analysis
6.1. Definitions and Scope
6.1.1. Oncology
6.1.1.1. Small Molecule
6.1.1.2. Biologics
6.1.2. Infectious Diseases
6.1.3. Neurological Disorders
6.1.4. Cardiovascular Diseases
6.1.5. Metabolic Disorders
6.1.6. Autoimmune Diseases
6.1.7. Respiratory Diseases
6.1.8. Ophthalmology
6.1.9. Gastrointestinal Disorders
6.1.10. Hormonal Disorders
6.1.11. Hematological Disorders
6.1.12. Others
6.2. Segment Dashboard
6.3. Global Pharmaceutical CDMO Market Movement Analysis
6.4. Global Pharmaceutical CDMO Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
6.4.1. Oncology
6.4.1.1. Market estimates and forecast 2018 to 2030 (USD million)
6.4.1.2. Small Molecule
6.4.1.2.1. Market estimates and forecast 2018 to 2030 (USD million)
6.4.1.3. Biologics
6.4.1.3.1. Market estimates and forecast 2018 to 2030 (USD million)
6.4.2. Infectious Diseases
6.4.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.3. Neurological Disorders
6.4.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.4. Cardiovascular Diseases
6.4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.5. Metabolic Disorders
6.4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.6. Autoimmune Diseases
6.4.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.7. Respiratory Diseases
6.4.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.8. Ophthalmology
6.4.8.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.9. Gastrointestinal Disorders
6.4.9.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.10. Hormonal Disorders
6.4.10.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.11. Hematological Disorders
6.4.11.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.12. Others
6.4.12.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 7. Pharmaceutical CDMO Market: Regional Estimates & Trend Analysis by Product, Workflow, & Application
7.1. Regional Market Dashboard
7.2. Global Regional Market Snapshot
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030
7.4. North America
7.4.1. Market estimates and forecast, 2021 - 2033
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Scenario
7.4.2.4. Market estimates and forecast, 2021 - 2033
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Scenario
7.4.3.4. Market estimates and forecast, 2021 - 2033
7.5. Europe
7.5.1. Market estimates and forecast, 2021 - 2033
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Scenario
7.5.2.4. Market estimates and forecast, 2021 - 2033
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Scenario
7.5.3.4. Market estimates and forecast, 2021 - 2033
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Scenario
7.5.4.4. Market estimates and forecast, 2021 - 2033
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Competitive Scenario
7.5.5.3. Regulatory Scenario
7.5.5.4. Market estimates and forecast, 2021 - 2033
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Competitive Scenario
7.5.6.3. Regulatory Scenario
7.5.6.4. Market estimates and forecast, 2021 - 2033
7.5.7. Denmark
7.5.7.1. Key Country Dynamics
7.5.7.2. Competitive Scenario
7.5.7.3. Regulatory Scenario
7.5.7.4. Market estimates and forecast, 2021 - 2033
7.5.8. Sweden
7.5.8.1. Key Country Dynamics
7.5.8.2. Competitive Scenario
7.5.8.3. Regulatory Scenario
7.5.8.4. Market estimates and forecast, 2021 - 2033
7.5.9. Norway
7.5.9.1. Key Country Dynamics
7.5.9.2. Competitive Scenario
7.5.9.3. Regulatory Scenario
7.5.9.4. Market estimates and forecast, 2021 - 2033
7.6. Asia Pacific
7.6.1. Market estimates and forecast, 2021 - 2033
7.6.2. China
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Scenario
7.6.2.4. Market estimates and forecast, 2021 - 2033
7.6.3. India
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Scenario
7.6.3.4. Market estimates and forecast, 2021 - 2033
7.6.4. Japan
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Scenario
7.6.4.4. Market estimates and forecast, 2021 - 2033
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Scenario
7.6.5.4. Market estimates and forecast, 2021 - 2033
7.6.6. South Korea
7.6.6.1. Key Country Dynamics
7.6.6.2. Competitive Scenario
7.6.6.3. Regulatory Scenario
7.6.6.4. Market estimates and forecast, 2021 - 2033
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Competitive Scenario
7.6.7.3. Regulatory Scenario
7.6.7.4. Market estimates and forecast, 2021 - 2033
7.7. Latin America
7.7.1. Market estimates and forecast, 2021 - 2033
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Competitive Scenario
7.7.2.3. Regulatory Scenario
7.7.2.4. Market estimates and forecast, 2021 - 2033
7.7.3. Mexico
7.7.3.1. Key Country Dynamics
7.7.3.2. Competitive Scenario
7.7.3.3. Regulatory Scenario
7.7.3.4. Market estimates and forecast, 2021 - 2033
7.7.4. Argentina
7.7.4.1. Key Country Dynamics
7.7.4.2. Competitive Scenario
7.7.4.3. Regulatory Scenario
7.7.4.4. Market estimates and forecast, 2021 - 2033
7.8. MEA
7.8.1. Market estimates and forecast, 2021 - 2033
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Competitive Scenario
7.8.2.3. Regulatory Scenario
7.8.2.4. Market estimates and forecast, 2021 - 2033
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Competitive Scenario
7.8.3.3. Regulatory Scenario
7.8.3.4. Market estimates and forecast, 2021 - 2033
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Competitive Scenario
7.8.4.3. Regulatory Scenario
7.8.4.4. Market estimates and forecast, 2021 - 2033
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Competitive Scenario
7.8.5.3. Regulatory Scenario
7.8.5.4. Market estimates and forecast, 2021 - 2033
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Pharmaceutical CDMO Market Share Analysis, 2023
8.3. Major Deals and Strategic Alliances Analysis
8.3.1. Strategy Mapping
8.3.2. Expansion
8.3.3. Partnerships
8.3.4. Acquisitions
8.4. Vendor Landscape
8.4.1. Key company market share analysis, 2023
8.4.2. Lonza
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Thermo Fisher Scientific, Inc.
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Recipharm AB
8.4.4.1. Company Overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Laboratory Corporation of America Holdings (LabCorp)
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Catalent, Inc.
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. WuXi AppTec, Inc.
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Samsung Biologics
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Piramal Pharma Solutions
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. Siegfried Holding AG
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives
8.4.11. CordenPharma International
8.4.11.1. Company overview
8.4.11.2. Financial performance
8.4.11.3. Product benchmarking
8.4.11.4. Strategic initiatives
8.4.12. Cambrex Corporation
8.4.12.1. Company overview
8.4.12.2. Financial performance
8.4.12.3. Product benchmarking
8.4.12.4. Strategic initiatives
8.4.13. Bushu Pharmaceuticals Ltd.
8.4.13.1. Company overview
8.4.13.2. Financial performance
8.4.13.3. Product benchmarking
8.4.13.4. Strategic initiatives
8.4.14. Nipro Corporation
8.4.14.1. Company overview
8.4.14.2. Financial performance
8.4.14.3. Product benchmarking
8.4.14.4. Strategic initiatives
8.4.15. Sequens
8.4.15.1. Company overview
8.4.15.2. Financial performance
8.4.15.3. Product benchmarking
8.4.15.4. Strategic initiatives
8.4.16. EuroAPI
8.4.16.1. Company overview
8.4.16.2. Financial performance
8.4.16.3. Product benchmarking
8.4.16.4. Strategic initiatives
8.4.17. Hovione
8.4.17.1. Company overview
8.4.17.2. Financial performance
8.4.17.3. Product benchmarking
8.4.17.4. Strategic initiatives
8.4.18. Axplora
8.4.18.1. Company overview
8.4.18.2. Financial performance
8.4.18.3. Product benchmarking
8.4.18.4. Strategic initiatives
8.4.19. Curia
8.4.19.1. Company overview
8.4.19.2. Financial performance
8.4.19.3. Product benchmarking
8.4.19.4. Strategic initiatives
8.4.20. Dottikon
8.4.20.1. Company overview
8.4.20.2. Financial performance
8.4.20.3. Product benchmarking
8.4.20.4. Strategic initiatives
8.4.21. Almac
8.4.21.1. Company overview
8.4.21.2. Financial performance
8.4.21.3. Product benchmarking
8.4.21.4. Strategic initiatives
8.4.22. FIS - Fabbrica Italiana Sintetici S.p.A.
8.4.22.1. Company overview
8.4.22.2. Financial performance
8.4.22.3. Product benchmarking
8.4.22.4. Strategic initiatives
8.4.23. Evonik
8.4.23.1. Company overview
8.4.23.2. Financial performance
8.4.23.3. Product benchmarking
8.4.23.4. Strategic initiatives
8.4.24. Carbogen Amcis
8.4.24.1. Company overview
8.4.24.2. Financial performance
8.4.24.3. Product benchmarking
8.4.24.4. Strategic initiatives
8.4.25. Farmhispania
8.4.25.1. Company overview
8.4.25.2. Financial performance
8.4.25.3. Product benchmarking
8.4.25.4. Strategic initiatives
8.4.26. Uquifa
8.4.26.1. Company overview
8.4.26.2. Financial performance
8.4.26.3. Product benchmarking
8.4.26.4. Strategic initiatives
8.4.27. Ajinomoto Bio-Pharma (Ajinomoto Co., Inc.)
8.4.27.1. Company Overview
8.4.27.2. Financial performance
8.4.27.3. Product benchmarking
8.4.27.4. Strategic initiatives
8.4.28. Pfizer Centre One
8.4.28.1. Company overview
8.4.28.2. Financial performance
8.4.28.3. Product benchmarking
8.4.28.4. Strategic initiatives
8.4.29. Fareva
8.4.29.1. Company Overview
8.4.29.2. Financial performance
8.4.29.3. Product benchmarking
8.4.29.4. Strategic initiatives
8.4.30. Sterling
8.4.30.1. Company overview
8.4.30.2. Financial performance
8.4.30.3. Product benchmarking
8.4.30.4. Strategic initiatives
8.4.31. Veranova
8.4.31.1. Company overview
8.4.31.2. Financial performance
8.4.31.3. Product benchmarking
8.4.31.4. Strategic initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers